FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2952542356> ?p ?o ?g. }

• W2952542356 endingPage "72" @default.
• W2952542356 startingPage "65" @default.
• W2952542356 abstract "The treatment of relapsed/refractory (R/R) acute myeloid leukaemia (AML) remains a challenge. Among salvage chemotherapy regimens, the clofarabine and cytarabine (CLARA) combination has been widely evaluated and has a favourable safety/efficacy balance. Predictive factors of efficacy in patients with R/R AML are unclear, particularly the impact of AML-related gene mutations. We report our single-centre experience on 34 R/R AML patients treated with CLARA, with a focus on the genetic characterization of our cohort. CLARA yielded a 47% response rate among this poor-prognosis AML population, while two patients (5·8%) died due to treatment-related toxicity. The two-year progression-free survival and overall survival rates were 29·4% and 35·3%, respectively. Nine patients (26%) had long-term response with a median follow-up of 39·5 months among the responders, of whom six underwent haematopoietic stem cell transplantation. Adverse karyotype did not correlate with response or survival, and secondary AML were more frequent among responders to CLARA, suggesting that this combination may successfully salvage R/R AML patients regardless of adverse prognostic markers. We also observed that a low mutational burden and absence of splice mutations correlated with prolonged survival after CLARA, suggesting that extensive genotyping may have prognostic implications in R/R AML." @default.
• W2952542356 created "2019-06-27" @default.
• W2952542356 creator A5001503693 @default.
• W2952542356 creator A5004158420 @default.
• W2952542356 creator A5007247346 @default.
• W2952542356 creator A5018074362 @default.
• W2952542356 creator A5033775906 @default.
• W2952542356 creator A5036907562 @default.
• W2952542356 creator A5040217631 @default.
• W2952542356 creator A5064856085 @default.
• W2952542356 creator A5075558296 @default.
• W2952542356 creator A5085975555 @default.
• W2952542356 creator A5089493611 @default.
• W2952542356 date "2019-06-18" @default.
• W2952542356 modified "2023-10-18" @default.
• W2952542356 title "Impact of genotype in relapsed and refractory acute myeloid leukaemia patients treated with clofarabine and cytarabine: a retrospective study" @default.
• W2952542356 cites W1255676896 @default.
• W2952542356 cites W1967196235 @default.
• W2952542356 cites W2040489908 @default.
• W2952542356 cites W2098290171 @default.
• W2952542356 cites W2102776788 @default.
• W2952542356 cites W2142751465 @default.
• W2952542356 cites W2150480709 @default.
• W2952542356 cites W2159746057 @default.
• W2952542356 cites W2160635204 @default.
• W2952542356 cites W2335899249 @default.
• W2952542356 cites W2339658711 @default.
• W2952542356 cites W2507166450 @default.
• W2952542356 cites W2513093633 @default.
• W2952542356 cites W2559537906 @default.
• W2952542356 cites W2563784492 @default.
• W2952542356 cites W2579563793 @default.
• W2952542356 cites W2593230508 @default.
• W2952542356 cites W2725930552 @default.
• W2952542356 cites W2802234295 @default.
• W2952542356 cites W2891678924 @default.
• W2952542356 cites W2899020069 @default.
• W2952542356 cites W4231346141 @default.
• W2952542356 cites W4234712695 @default.
• W2952542356 cites W4240636810 @default.
• W2952542356 doi "https://doi.org/10.1111/bjh.16045" @default.
• W2952542356 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31215036" @default.
• W2952542356 hasPublicationYear "2019" @default.
• W2952542356 type Work @default.
• W2952542356 sameAs 2952542356 @default.
• W2952542356 citedByCount "3" @default.
• W2952542356 countsByYear W29525423562019 @default.
• W2952542356 countsByYear W29525423562021 @default.
• W2952542356 countsByYear W29525423562022 @default.
• W2952542356 crossrefType "journal-article" @default.
• W2952542356 hasAuthorship W2952542356A5001503693 @default.
• W2952542356 hasAuthorship W2952542356A5004158420 @default.
• W2952542356 hasAuthorship W2952542356A5007247346 @default.
• W2952542356 hasAuthorship W2952542356A5018074362 @default.
• W2952542356 hasAuthorship W2952542356A5033775906 @default.
• W2952542356 hasAuthorship W2952542356A5036907562 @default.
• W2952542356 hasAuthorship W2952542356A5040217631 @default.
• W2952542356 hasAuthorship W2952542356A5064856085 @default.
• W2952542356 hasAuthorship W2952542356A5075558296 @default.
• W2952542356 hasAuthorship W2952542356A5085975555 @default.
• W2952542356 hasAuthorship W2952542356A5089493611 @default.
• W2952542356 hasBestOaLocation W29525423561 @default.
• W2952542356 hasConcept C126322002 @default.
• W2952542356 hasConcept C142424586 @default.
• W2952542356 hasConcept C143998085 @default.
• W2952542356 hasConcept C167135981 @default.
• W2952542356 hasConcept C197934379 @default.
• W2952542356 hasConcept C2776694085 @default.
• W2952542356 hasConcept C2777198975 @default.
• W2952542356 hasConcept C2777408962 @default.
• W2952542356 hasConcept C2778041864 @default.
• W2952542356 hasConcept C2778729363 @default.
• W2952542356 hasConcept C2780775027 @default.
• W2952542356 hasConcept C2908647359 @default.
• W2952542356 hasConcept C2911091166 @default.
• W2952542356 hasConcept C71924100 @default.
• W2952542356 hasConcept C86803240 @default.
• W2952542356 hasConcept C87355193 @default.
• W2952542356 hasConcept C90924648 @default.
• W2952542356 hasConcept C99454951 @default.
• W2952542356 hasConceptScore W2952542356C126322002 @default.
• W2952542356 hasConceptScore W2952542356C142424586 @default.
• W2952542356 hasConceptScore W2952542356C143998085 @default.
• W2952542356 hasConceptScore W2952542356C167135981 @default.
• W2952542356 hasConceptScore W2952542356C197934379 @default.
• W2952542356 hasConceptScore W2952542356C2776694085 @default.
• W2952542356 hasConceptScore W2952542356C2777198975 @default.
• W2952542356 hasConceptScore W2952542356C2777408962 @default.
• W2952542356 hasConceptScore W2952542356C2778041864 @default.
• W2952542356 hasConceptScore W2952542356C2778729363 @default.
• W2952542356 hasConceptScore W2952542356C2780775027 @default.
• W2952542356 hasConceptScore W2952542356C2908647359 @default.
• W2952542356 hasConceptScore W2952542356C2911091166 @default.
• W2952542356 hasConceptScore W2952542356C71924100 @default.
• W2952542356 hasConceptScore W2952542356C86803240 @default.
• W2952542356 hasConceptScore W2952542356C87355193 @default.
• W2952542356 hasConceptScore W2952542356C90924648 @default.
• W2952542356 hasConceptScore W2952542356C99454951 @default.

• next